This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

This study has been terminated.
(insufficient patient recruitment)
Information provided by (Responsible Party):
Devirex AG Identifier:
First received: December 14, 2012
Last updated: August 4, 2014
Last verified: August 2014
The aim of this study is therefore to investigate the efficacy of the PEG-formulation to reduce the frequency and duration of genital herpes recurrences, to assess its safety and tolerability and to investigate its effect on shedding.

Condition Intervention Phase
Genital Herpes Drug: PEG-Formulation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes

Resource links provided by NLM:

Further study details as provided by Devirex AG:

Primary Outcome Measures:
  • Change of number of genital herpes recurrences during the treatment period as compared to the baseline period. [ Time Frame: Baseline and Treatment period (6 months each). ]
    The number of genital herpes recurrences will be counted during the baseline period (6 months) and during the treatment period (6 months) and then be compared.

Secondary Outcome Measures:
  • The safety of the PEG-formulation via reporting of AEs. [ Time Frame: Baseline and Treatment period (6 months each). ]

Other Outcome Measures:
  • The frequency of days with viral shedding which will be analysed by quantitative PCR. [ Time Frame: Baseline and Treatment period (6 months each). ]

Enrollment: 8
Study Start Date: February 2013
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PEG-Formulation
PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
Drug: PEG-Formulation


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed Consent
  • 18 - 65 years
  • Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)
  • Initial infection > 1 year ago
  • ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy)
  • ≥ 2 recurrences during the six-month baseline period

Exclusion Criteria:

  • Known or suspected allergy or intolerability to PEG
  • Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial
  • Pregnancy and/or breast-feeding
  • History of malignant diseases (described in chapter 7.2)
  • Known or suspected non-compliance to study protocol
  • Participation in another investigational drug study in the last 30 days prior to baseline period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01765114

University Hospital Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
Devirex AG
Principal Investigator: Thomas Kuendig, MD University of Zurich
  More Information

Responsible Party: Devirex AG Identifier: NCT01765114     History of Changes
Other Study ID Numbers: DEV-PEG-02
Study First Received: December 14, 2012
Last Updated: August 4, 2014

Additional relevant MeSH terms:
Herpes Genitalis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Genital Diseases, Male
Genital Diseases, Female processed this record on September 21, 2017